Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020, 164(2):138-140 | DOI: 10.5507/bp.2020.024

Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA

David Stejskal^a,b,c, Radka Sigutova^a,b, Marek Svestak^c, Jan Vaclavik^d, Pavlina Kusnierova^a,b, Zdenek Svagera^a,b

^a Institute of Laboratory Diagnostics, University Hospital Ostrava, Czech Republic

^b Institute of Biomedical Sciences, University of Ostrava, Czech Republic

^c Department of Biochemistry, Stredomoravska nemocnicni, Member of Agel, Czech Republic

^d Department of Internal Medicine I - Cardiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic

Objectives: Adipose tissue produces a number of adipokines that have metabolic effect. Visfatin is a recently discovered adipokine whose concentration in plasma increases in obesity. It is also a proinflammatory mediator that promotes atherosclerosis and plays a role in plaque destabilization. The aim of this study was to evaluate an assay for the determination of visfatin in human plasma and to investigate its clinical relevance as a marker of acute coronary syndrome (ACS) in a young population (Men under 45 y, Women under 55 y). Design and Methods: We clinically tested a sandwich ELISA assay in young individuals with acute myocardial infarction (n=36) vs. a control group (n=21). The control sample was a healthy proband without inflammation, hepatic or renal injury and under 55 years of age.

Results: Visfatin in plasma was able to differentiate the control group from young patients with acute myocardial infarction (5 vs. 27 ng/L). Visfatin in the plasma of acute myocardial infarction (AMI) probands, correlated in individuals with acute coronary syndrome was related to plasma glucose (r=0.47; P=0.01), type 2 diabetes mellitus (r=0.65; P=0.01), plasma creatinine concentration (r=0.3, P=0.02), hsCRP (r=0.29; P=0.03), BMI values (r=0.18; P=0.04), triglycerides (r=0.5; P=0.01) and NT-proBNP (r=0.21; P=0.04). In healthy subjects, these relations were not found. ROC analysis: visfatin cut-off concentration was 20 ng/L with a sensitivity of 84% and a specificity of 90%. The area under the curve (AUC) of cTNI was 0.96, the AUC of visfatin was 0.96. Thus, there was no difference.

Conclusion: We conclude that visfatin in serum may be a new independent potential marker of AMI.

Keywords: visfatin, acute myocardial infarction, adipokines, ELISA

Received: July 2, 2019; Revised: March 26, 2020; Accepted: May 12, 2020; Prepublished online: June 1, 2020; Published: June 18, 2020  Show citation